{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:23:52Z","timestamp":1791998632752,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijrobp.2026.04.026","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:26:19Z","timestamp":1776871579000},"page":"672-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial"],"prefix":"10.1016","volume":"126","author":[{"given":"Yunjie","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-1433","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.04.026_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0002","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(17)31462-9","article-title":"Oesophageal cancer","volume":"390","author":"Lagergren","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0003","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0004","first-page":"150","article-title":"Quality of life and survival outcomes of patients with inoperable esophageal squamous cell carcinoma after definitive radiation therapy: A multicenter retrospective observational study in China from 2015 to 2016","volume":"3","author":"Wang","year":"2023","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0005","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.3390\/curroncol29090499","article-title":"Consolidation chemotherapy rather than induction chemotherapy can prolong the survival rate of inoperable esophageal cancer patients who received concurrent chemoradiotherapy","volume":"29","author":"Xia","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0006","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","article-title":"Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG Oncology RTOG 0436 phase 3 randomized clinical trial","volume":"3","author":"Suntharalingam","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0007","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0009","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0013","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0014","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115666","article-title":"Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A real-world multicenter study","volume":"167","author":"Yu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s43018-025-00918-1","article-title":"Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma \u2013 A multicenter phase 2 trial (EPOC1802)","volume":"6","author":"Bando","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0017","doi-asserted-by":"crossref","first-page":"S1101","DOI":"10.1016\/j.annonc.2025.08.2716","volume":"36","author":"Chau","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0018","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12601","article-title":"Concurrent chemoradiotherapy of different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial","volume":"44","author":"Zhang","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102806","article-title":"Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: Insights from the EC-CRT-001 phase II trial","volume":"75","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0020","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0021","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0022","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","article-title":"High-dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, phase 3 superiority trial","volume":"115","author":"You","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0023","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0024","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-24-4123","article-title":"Radiation dose-volume effects on negative tumor-draining lymph nodes affected T-cell activation and prognosis in esophageal cancer with chemoradiotherapy","volume":"31","author":"Tseng","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1971418","article-title":"Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: A phase 1b study","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0026","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/1759-7714.12178","article-title":"Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients","volume":"6","author":"Wu","year":"2015","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0028","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1007\/s00330-020-06931-5","article-title":"Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE","volume":"30","author":"Schobert","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0029","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.21873\/anticanres.15781","article-title":"Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer","volume":"42","author":"Booka","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0030","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.21873\/anticanres.17160","article-title":"Maximum efficacy of immune checkpoint inhibitors occurs in esophageal cancer patients with a low neutrophil-to-lymphocyte ratio and good performance status prior to treatment","volume":"44","author":"Hirasawa","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.026_bib0031","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: A phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626006012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626006012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:07:57Z","timestamp":1790366877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626006012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0360301626006012"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.026","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidative Camrelizumab Following Definitive Concurrent Chemoradiation Therapy With Involved-Field Irradiation in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}